Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3706674 oral monotherapy dose-finding trial in KRAS wild-type amplified gastric, esophageal, and gastroesophageal junction cancers
jRCT2030230343Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of BI 3706674 in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and 1 more, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of dose-limiting toxicities. Started Dec 2023; status: active, not recruiting.
02
Drugs
BI 3706674
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2030230343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030230343.